Zepbound Cost in Michigan 2026: Pricing, Insurance, and Savings Options

Zepbound List Price and Retail Cost in Michigan

The manufacturer list price set by Eli Lilly for Zepbound is $1,059 per month, regardless of dose strength. This price applies uniformly across all Michigan retail pharmacies, from CVS and Walgreens locations in Detroit to independent pharmacies in Traverse City or Marquette.

That $1,059 figure represents the wholesale acquisition cost (WAC) before any insurance negotiation, discount card, or pharmacy benefit manager (PBM) rebate. Patients paying full cash price at a Michigan retail pharmacy will encounter this number at the counter. The price remains consistent across all six dose tiers (2.5 mg through 15 mg), which means dose escalation does not increase monthly cost [1].

For context on the drug's clinical value at this price point: the SURMOUNT-1 trial (N=2,539) demonstrated that tirzepatide 15 mg produced 22.5% mean body weight reduction at 72 weeks compared to 3.1% with placebo [2]. That level of weight loss had previously required bariatric surgery. The 10 mg dose produced 19.5% mean weight loss, and even the 5 mg dose delivered 15.0%, all statistically significant with P<0.001 versus placebo.

Michigan's average household income and cost of living sit below the national median, making the uninsured list price particularly burdensome for many residents. But few patients should pay that full amount. The sections below cover every available discount pathway.

Insurance Coverage for Zepbound in Michigan

Commercial insurance coverage for Zepbound varies widely across Michigan carriers. Blue Cross Blue Shield of Michigan (BCBSM), the state's largest insurer, covers Zepbound on its pharmacy formulary with prior authorization for qualifying members. Priority Health, HAP (Health Alliance Plan), and McLaren Health Plan each maintain their own formulary placement and step therapy requirements.

Prior authorization criteria typically mirror the FDA label: BMI ≥30 kg/m², or BMI ≥27 kg/m² with at least one weight-related comorbidity such as type 2 diabetes, hypertension, dyslipidemia, or obstructive sleep apnea. Some plans require documentation of a failed 3-to-6-month trial of lifestyle modification before approval. A smaller number of Michigan plans still exclude anti-obesity medications entirely from coverage, particularly self-funded employer plans [1].

"Prior authorization for GLP-1 receptor agonists used in weight management is the norm, not the exception, and clinicians should prepare thorough documentation at the time of prescribing," according to the Endocrine Society's 2024 clinical practice guideline on pharmacological management of obesity [3].

When a Michigan commercial plan does cover Zepbound, member copays range from $25 to $150 per month depending on formulary tier. Specialty tier placement pushes copays higher. Patients should call the number on the back of their insurance card and ask specifically whether tirzepatide for chronic weight management (not diabetes) is a covered benefit, because the answer differs from Mounjaro coverage under the diabetes indication.

Eli Lilly Savings Card: How It Works in Michigan

Eli Lilly offers the Zepbound Savings Card program to commercially insured patients across all 50 states, including Michigan. Eligible patients pay as little as $25 per month for their Zepbound prescription.

Eligibility requirements are straightforward. The patient must have commercial insurance (not Medicare, Medicaid, or Tricare), must have a valid prescription, and must fill at a participating pharmacy. The card covers the difference between the patient's insurance copay and $25, up to a maximum benefit of $563 per 28-day supply. The program has no income verification [1].

Michigan patients without any insurance coverage for Zepbound can still use a separate Lilly cash-pay program. This direct-purchase option lets uninsured or coverage-denied patients obtain single-dose vials of tirzepatide at reduced pricing through Lilly's LillyDirect platform, with prices starting at $399 for a one-month supply of the 2.5 mg or 5 mg dose.

To activate the savings card, Michigan patients can visit the Zepbound website, complete the eligibility screening, and download the card digitally. The card is presented to the pharmacist at the time of fill. Processing occurs through the pharmacy's adjudication system in real time.

One practical tip: if a Michigan pharmacy initially runs the prescription without the savings card and the claim adjudicates at full price, the pharmacist can reverse and rebill with the savings card information. Patients should not leave the pharmacy counter without confirming the savings card was applied.

Michigan Medicaid Coverage for Zepbound

Michigan Medicaid covers Zepbound with prior authorization. This makes Michigan one of the states where Medicaid beneficiaries have a defined pathway to access tirzepatide for chronic weight management [4].

The Michigan Department of Health and Human Services (MDHHS) administers Medicaid pharmacy benefits through its managed care organizations, including Molina Healthcare of Michigan, Meridian Health Plan, Aetna Better Health of Michigan, and others. Each managed care plan may apply its own prior authorization form and clinical criteria, but the underlying state-level coverage decision permits Zepbound access.

PA criteria for Michigan Medicaid generally require a documented BMI meeting FDA label thresholds, evidence of weight-related comorbidity, and a trial of lifestyle intervention. Some plans require failure of an older anti-obesity agent (phentermine or orlistat) before approving tirzepatide. Prescribers should check the specific managed care plan's preferred drug list and submit a completed PA request with supporting chart notes, lab values, and BMI documentation.

Processing time for Michigan Medicaid PA requests averages 3 to 5 business days for standard requests. Urgent requests may be completed within 24 hours. If denied, patients have the right to appeal through the managed care grievance process and, if necessary, through a Michigan Administrative Hearing.

Compounded Tirzepatide in Michigan: Legality, Cost, and Considerations

Compounded tirzepatide is available in Michigan through licensed 503A compounding pharmacies at an average cost of $249 per month. This represents a 76% savings compared to the brand-name list price.

503A pharmacies compound medications pursuant to individual patient prescriptions under state pharmacy board oversight. Michigan's Board of Pharmacy licenses and inspects these facilities. A valid prescription from a licensed prescriber is required for each patient [5].

The legal status of compounded tirzepatide depends on the FDA's drug shortage list. As of early 2026, tirzepatide remained on the FDA shortage list, which permits 503A pharmacies to compound copies of commercially available drugs. If the FDA formally resolves the shortage, the legal basis for compounding shifts, and 503A pharmacies would need to demonstrate that their compounded product is "not essentially a copy" of the commercial drug or operate under a different regulatory pathway [5].

Michigan patients considering compounded tirzepatide should verify several things. The compounding pharmacy should hold a valid Michigan Board of Pharmacy license. It should perform potency and sterility testing on each batch. The pharmacy should provide a Certificate of Analysis upon request. And the prescribing clinician should be willing to monitor the patient on the compounded product with the same rigor as the branded version.

"Patients and prescribers should be aware that compounded drugs are not FDA-approved and have not undergone FDA review for safety, effectiveness, or quality," the FDA states in its guidance on compounding [5]. This is not a prohibition. It is a transparency requirement. Compounded tirzepatide from a reputable 503A pharmacy contains the same active molecule, but manufacturing oversight differs from Eli Lilly's FDA-inspected production facilities.

Price comparison across Michigan access routes:

• Brand Zepbound (cash): $1,059/month
• Brand Zepbound (with Lilly savings card + commercial insurance): as low as $25/month
• Brand Zepbound (LillyDirect cash-pay vials): starting at $399/month
• Compounded tirzepatide (503A): approximately $249/month
• Michigan Medicaid (with PA approved): $0 to $3 copay

Getting Zepbound via Telehealth in Michigan

Michigan fully permits telehealth prescribing of Zepbound. Patients anywhere in the state, from the Upper Peninsula to metro Detroit, can consult with a licensed prescriber via video or audio visit and receive a tirzepatide prescription without an in-person office visit.

Michigan's telehealth parity laws, updated during and after the COVID-19 public health emergency, allow prescribers to establish a patient-provider relationship through synchronous telehealth. The Michigan Public Health Code does not require an in-person visit before prescribing Schedule III-V or non-controlled medications, and Zepbound is not a controlled substance [6].

Multiple telehealth platforms operate in Michigan and prescribe Zepbound. Patients should confirm three things before selecting a provider: the prescriber holds an active Michigan medical license, the platform prescribes brand-name Zepbound (not only compounded versions), and the platform assists with insurance prior authorization if the patient has coverage.

Telehealth visits for weight management in Michigan typically cost between $50 and $199 for an initial consultation. Some platforms bundle ongoing monthly check-ins with the prescription service. Patients with commercial insurance may have telehealth visits covered under their plan's office visit benefit.

Manufacturer Patient Assistance and Michigan-Specific Programs

Beyond the savings card, Eli Lilly operates the Lilly Cares Foundation patient assistance program for uninsured patients whose household income falls at or below 400% of the federal poverty level (FPL). For a single-person household in 2026, that threshold is approximately $62,400 annually. Approved applicants receive Zepbound at no cost [1].

The application requires proof of income (tax return or pay stubs), proof of U.S. residency, a completed prescriber certification form, and documentation that the patient lacks prescription drug coverage. Processing takes 4 to 6 weeks. Michigan patients can call 1-800-545-6962 to request an application.

Michigan also has state-level pharmacy assistance programs. The Michigan Medicare/Medicaid Assistance Program (MMAP) provides counseling to dual-eligible beneficiaries who may have coverage through both programs. While MMAP does not directly pay for medications, its counselors help patients identify the lowest-cost coverage pathway.

For Michigan residents enrolled in Medicare Part D, Zepbound coverage remains limited. Most Part D plans do not cover anti-obesity medications, as the Medicare statute historically excluded weight-loss drugs. The Treat and Reduce Obesity Act, if passed, would change this. Until then, Medicare beneficiaries in Michigan face the full cash price unless they qualify for Lilly Cares or use compounded tirzepatide.

Dose Escalation Schedule and Cost Implications

Zepbound's FDA-approved titration starts at 2.5 mg weekly for 4 weeks, then increases to 5 mg weekly. From there, the prescriber may increase the dose by 2.5 mg increments at minimum 4-week intervals up to the maximum 15 mg weekly dose [1].

A practical cost advantage: because Eli Lilly prices all Zepbound doses identically at $1,059 per month, patients do not face rising costs as their dose escalates. This contrasts with some compounded tirzepatide pricing, where higher doses may cost more due to increased active pharmaceutical ingredient per vial.

The SURMOUNT-1 trial demonstrated dose-dependent weight loss: 15.0% at 5 mg, 19.5% at 10 mg, and 22.5% at 15 mg after 72 weeks [2]. Not every patient requires the maximum dose. In clinical practice, many patients achieve satisfactory weight loss at 10 mg or even 7.5 mg, and their prescriber may hold the dose at that level rather than escalating to 15 mg. This clinical flexibility does not affect brand cost but may affect compounded cost.

The American Association of Clinical Endocrinology (AACE) 2023 obesity algorithm recommends titrating anti-obesity medications to the dose that produces adequate weight loss (defined as ≥10% at 6 months) with acceptable tolerability, rather than reflexively escalating to the maximum approved dose [7].

Side Effects, Monitoring, and When to Contact Your Michigan Provider

The most common side effects of tirzepatide are gastrointestinal: nausea (reported by 24-33% of patients in SURMOUNT-1), diarrhea (17-23%), constipation (11-17%), and vomiting (6-12%), with rates varying by dose [2]. These effects are typically most pronounced during dose escalation and diminish over 4 to 8 weeks at a stable dose.

Michigan patients should contact their prescriber if they experience persistent vomiting lasting more than 48 hours, signs of pancreatitis (severe abdominal pain radiating to the back), symptoms consistent with gallbladder disease (right upper quadrant pain after meals), or any allergic reaction including facial swelling or difficulty breathing [1].

Recommended baseline labs before starting Zepbound include a comprehensive metabolic panel, lipid panel, hemoglobin A1c, and thyroid function tests. The FDA label carries a boxed warning regarding thyroid C-cell tumors based on rodent studies, though this risk has not been confirmed in humans. Tirzepatide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 [1].

Michigan prescribers should also screen for a history of bariatric surgery, as post-surgical anatomy may affect GI tolerability, and for concurrent use of insulin or sulfonylureas, which require dose adjustment to prevent hypoglycemia when combined with tirzepatide.

Comparing Zepbound to Other Weight Management Options in Michigan

Michigan patients evaluating anti-obesity medications have several alternatives to consider. Wegovy (semaglutide 2.4 mg) carries a list price of $1,349 per month, higher than Zepbound. The STEP-1 trial (N=1,961) demonstrated 14.9% mean weight loss at 68 weeks with semaglutide 2.4 mg versus 2.4% with placebo [8]. Tirzepatide's dual GIP/GLP-1 mechanism produced numerically greater weight loss in SURMOUNT-1, though no head-to-head trial has directly compared the two drugs for the obesity indication.

Older options like phentermine-topiramate ER (Qsymia) cost $150 to $250 per month cash and produce approximately 10% weight loss at the high dose [9]. Orlistat is available over the counter as Alli ($40 to $60 per month) but produces only 3-5% weight loss. Contrave (naltrexone-bupropion) averages $100 to $200 per month with modest 5-6% weight loss.

For Michigan Medicaid patients who face step therapy requirements, starting with phentermine (generic, $15 to $30 per month) may be required before Zepbound approval. This is a formulary management decision, not a clinical recommendation that phentermine is the better first-line agent.